Vascular-targeted TNFα improves tumor blood vessel function and enhances antitumor immunity and chemotherapy in colorectal cancer

Lü, Lei; Li, Zhi Jie; Li, Long Fei; Wu, William Ka Kei; Shen, Jing; Zhang, Lin; Chan, Ruby Lok Yi; Yu, Li; Liu, Ya Wei; Ren, Shun X.; Chan, Kam Ming; Cho, Chi Hin

doi:10.1016/j.jconrel.2015.05.282

Cited by 30 publications

(24 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vascular targeted delivery of TNFα by TCP‐1 peptide (that specifically binds to the vasculature of colorectal cancer) inhibits tumor growth, induces apoptosis and increases antitumor immunity in orthotopic CRC model (Shen et al, ). Moreover TCP‐1‐conjugated TNFα combined with 5‐FU synergistically induces anti‐tumor effects in an in orthotopic CRC model (Lu et al, ).…”

Section: Death Receptor Signaling Pathwaymentioning

confidence: 99%

Targeting the death receptor signaling pathway as a potential therapeutic target in the treatment of colorectal cancer

Marjaneh

Hassanian

Ghobadi

et al. 2018

Journal Cellular Physiology

View full text Add to dashboard Cite

Despite advances in the diagnosis and treatment of colorectal cancer (CRC), it remains a major cause of cancer related death globally. There are currently no chemotherapeutic agents that have been found to eradicate the disease without adverse effects. A defect in the death receptor signaling pathway is a feature of CRC. The ligand of these receptors belongs to the tumor necrosis factor family, and that are particularly expressed by cells of the immune system, and that induce apoptosis in a caspase dependent manner. The fact that malignant cells are particularly sensitive to these ligands, compared to normal cells, has led to work on the assessment of compounds that activate this pathway in the treatment of CRC. Phase I trials have shown that these death receptor agonists are safe. Phase II and III trials are currently investigating the efficacy of these therapeutic agents in the treatment of CRC. In this review, we describe the biochemical death receptor signaling pathway and its relationship to CRC. We also summarize the current clinical studies that are targeting this signaling pathway in CRC treatment.

show abstract

Section: Death Receptor Signaling Pathwaymentioning

confidence: 99%

Targeting the death receptor signaling pathway as a potential therapeutic target in the treatment of colorectal cancer

Marjaneh

Hassanian

Ghobadi

et al. 2018

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…The data on experimental studies of cytokine application as a part of a combined therapy for colorectal carcinoma seemed to be inspiring [71][72][73][74]; however, clinical trials have shown contradictory results. Initially high expectations in colon cancer treatment were related to the use of interferons, since they have a direct and indirect (mediated via immunocompetent cells) antitumor effect: suppression of tumor cell proliferation, induction of their apoptosis, increased of МНС class I molecules expression, stimulation of NK and cytotoxic cells, anti-angiogenic effect [75].…”

Section: Application Of Cytokines In Colon Cancer Immunotherapymentioning

confidence: 99%

Colorectal Cancer Immunotherapy: Current State and Prospects (Review)

Kirichenko¹,

Novikova²,

Maksimov³

et al. 2017

Sovrem Tehnol Med

View full text Add to dashboard Cite

., Rostov-on-Don, 344006, Russian Federation Currently, new knowledge on immunotherapy in solid tumors is being intensively accumulated and new promising techniques are originating. The most advanced are those in the field of searching for new immune checkpoints, development of highly efficient immune adjuvants based on recombinant viruses to improve the effect of anticancer vaccines, as well as design engineering of chimeric receptors of T cells used for adoptive immunotherapy. We have presented some clinical trial results of immunotherapeutic approaches, as well as experimental studies on animal models, which offer new prospects for colon cancer treatment.

show abstract

“…This was always followed by an increase in the cancer cell resistance, despite excellent primary apoptosis results . Thus, clinical tests failed due to increasing toxicity and inflammatory response during the TRAIL administration (even with doses 10 to 50 times lower than the expected one for the treatment), while very promising.…”

Section: Introductionmentioning

confidence: 99%

Ligand nanovectorization using graphene to target cellular death receptors of cancer cell

2019

View full text Add to dashboard Cite

Tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) is nowadays envisaged as a natural cytokine useful in nanomedicine to eradicate the cancer cells and not the healthy surrounding ones. However, it suffers from cell resistance and strong dispersion in body to prove its efficiency. The understanding at the molecular level of the TRAIL interaction with death receptors (DRs) on cancer cells is thus of fundamental importance to improve its action. We demonstrate here via molecular simulations that TRAIL can bind to its both agonistic DRs (ie, DR4 and DR5) with a preference for DR4. In this study, the role of a graphene nanoflake as a potential cargo for TRAIL is examined. Furthermore, both TRAIL self‐assembling and TRAIL affinity when adsorbed on graphene are considered to enhance efficacy toward the targeted cancer cell. Our modelization results show that TRAIL can bind to DR4 and DR5 when transported by graphene nanoflake, as a proof of concept.

show abstract

Vascular-targeted TNFα improves tumor blood vessel function and enhances antitumor immunity and chemotherapy in colorectal cancer

Cited by 30 publications

References 55 publications

Targeting the death receptor signaling pathway as a potential therapeutic target in the treatment of colorectal cancer

Targeting the death receptor signaling pathway as a potential therapeutic target in the treatment of colorectal cancer

Colorectal Cancer Immunotherapy: Current State and Prospects (Review)

Ligand nanovectorization using graphene to target cellular death receptors of cancer cell

Contact Info

Product

Resources

About